PALO ALTO, CA, March 12, 2014 /PRNewswire/ – The PAWS Pet Company, Inc.
(OTCQB:PAWS), is pleased to announce that revised February orders at
its Mesa Pharmacy, Inc. (Mesa) subsidiary generated gross revenues,
excluding allowances for returns and discounts, exceeding $7.4 Million
Dollars. Prescription orders for transdermal topical pain medications
continue to rise.
Additionally, the Company has paid in full the only short-term
convertible note that was negotiated with Asher Enterprises, Inc. in
2013. The Company has settled all of its outstanding 14% Convertible
Debentures and intends to settle all remaining 8% Debentures in the
very near future.
In other news, the Company anticipates bringing on a new line of
business in the form of genetic testing. The Company anticipates
significant revenues from this new and exciting line of business if
negotiations can be concluded successfully. The Company will update
shareholders as events warrant.
Finally, work continues on the upcoming name change to Praxsyn
Corporation. The Company expects to complete the process in the very
near future.
About The PAWS Pet Company, Inc.
The PAWS Pet Company, Inc. is undergoing a transition from the pet space
to the pharmaceutical space. This exciting transition strategy has been
developed to take advantage of the changes underway in traditional
medical services. PAWS believes that great opportunities exist in
pharmaceuticals and how they are delivered to the public.
About Mesa Pharmacy, Inc.
Mesa focuses on providing custom compounded non-narcotic, transdermal
topical pain medications that are marketed to industrial health
physicians and clinics. Mesa compounds a series of topical prescription
medications, in different strengths, that provide the pain relief
doctors seek and that have a very low propensity for addiction. As a
result, physicians and insurers need not worry about treating an
injured worker and winding up having to treat that worker’s potential
addiction to pain killing narcotics.
For more information on The PAWS Pet Company go to: www.thepawspetcompany.com
Forward-Looking Statements
The statements contained herein may include statements of future
expectations and other forward-looking statements that are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements that are
forward-looking by reason of context, the words “may”, “will”,
“should”, “expects”, “plans”, “intends”, “anticipates”, “believes”,
“estimates”, “predicts”, “potential”, or “continue” and similar
expressions identify forward-looking statements (within the meaning of
the Private Securities Litigation Reform Act of 1995).
The actual results may differ materially from those described or
contemplated and consequently, you should not rely on these
forward-looking statements as predictions of future events. Certain of
these risks and uncertainties are discussed in the reports we filed
with the SEC.
SOURCE The PAWS Pet Company, Inc.
(OTCQB:PAWS), is pleased to announce that revised February orders at
its Mesa Pharmacy, Inc. (Mesa) subsidiary generated gross revenues,
excluding allowances for returns and discounts, exceeding $7.4 Million
Dollars. Prescription orders for transdermal topical pain medications
continue to rise.
Additionally, the Company has paid in full the only short-term
convertible note that was negotiated with Asher Enterprises, Inc. in
2013. The Company has settled all of its outstanding 14% Convertible
Debentures and intends to settle all remaining 8% Debentures in the
very near future.
In other news, the Company anticipates bringing on a new line of
business in the form of genetic testing. The Company anticipates
significant revenues from this new and exciting line of business if
negotiations can be concluded successfully. The Company will update
shareholders as events warrant.
Finally, work continues on the upcoming name change to Praxsyn
Corporation. The Company expects to complete the process in the very
near future.
About The PAWS Pet Company, Inc.
The PAWS Pet Company, Inc. is undergoing a transition from the pet space
to the pharmaceutical space. This exciting transition strategy has been
developed to take advantage of the changes underway in traditional
medical services. PAWS believes that great opportunities exist in
pharmaceuticals and how they are delivered to the public.
About Mesa Pharmacy, Inc.
Mesa focuses on providing custom compounded non-narcotic, transdermal
topical pain medications that are marketed to industrial health
physicians and clinics. Mesa compounds a series of topical prescription
medications, in different strengths, that provide the pain relief
doctors seek and that have a very low propensity for addiction. As a
result, physicians and insurers need not worry about treating an
injured worker and winding up having to treat that worker’s potential
addiction to pain killing narcotics.
For more information on The PAWS Pet Company go to: www.thepawspetcompany.com
Forward-Looking Statements
The statements contained herein may include statements of future
expectations and other forward-looking statements that are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements that are
forward-looking by reason of context, the words “may”, “will”,
“should”, “expects”, “plans”, “intends”, “anticipates”, “believes”,
“estimates”, “predicts”, “potential”, or “continue” and similar
expressions identify forward-looking statements (within the meaning of
the Private Securities Litigation Reform Act of 1995).
The actual results may differ materially from those described or
contemplated and consequently, you should not rely on these
forward-looking statements as predictions of future events. Certain of
these risks and uncertainties are discussed in the reports we filed
with the SEC.
SOURCE The PAWS Pet Company, Inc.
Read more at http://www.redorbit.com/news/health/1113093604/mesa-pharmacy-prescription-orders-for-february-exceed-74-million-sales/#Jp208pCRF6AEE1Sw.99
No comments:
Post a Comment